Air T ( AIRT) shares jumped nearly 9% in after-hours trading Tuesday after the Maiden, N.C.-based air-delivery company announced that the Air Force ordered about $13.8 million worth of its mobile de-icing trucks -- 43 in total. Shares were rising 67 cents to $8.20 in recent extended trading.

Sapient ( SAPE), a business-software and marketing-services firm, said its non-GAAP income from continuing operations totaled $7.9 million, or 6 cents a share, in the fourth quarter -- a 4-cent per-share drop from last year, but 4 cents higher than Wall Street expectations, according to Thomson Financial. Revenue surged 38% to $119.2 million, handily beating the $110.4 million consensus.

In 2007 the Cambridge, Mass., company expects sales in excess of $500 million. Analysts are looking for $491.2 million. Shares were adding 49 cents, or 8.2%, to $6.50.

Gymboree ( GYMB) got a lift after the children's-apparel retailer posted a profit of 84 cents a share (excluding a 2-cent settlement-related charge) in the quarter ended Feb. 3, which sprints past Wall Street's 72-cent per-share projections. Gymboree stock was gaining $2.28, or 6.5%, to $37.42.

Horse race-betting Web site Youbet.com ( UBET) rose after adjusted losses came to 3 cents a share, which beat ithe Street's call for 6-cent losses. Shares of the Woodland Hills, Calif., company were up 11 cents, or 3.9%, to $2.95.

Diamond ( DTPI), a Chicago-based management-consulting firm, slumped after tamping down its guidance for the quarter already in progress. It now projects earnings of between 6 cents and 7 cents a share, compared with its prior outlook of 8 cents to 10 cents. Wall Street is seeking 9 cents a share.

Revenue should now range between $41.5 million and $42.5 million -- at least $3.8 million under targets -- compared with the company's previous forecast of $44 million to $47 million. Shares were off $1.65, or 11.1%, to $13.20.

Maxygen ( MAXY) slid after Switzerland's Roche decided to terminate its yearlong agreement with the California-based biotech regarding development of Maxy-VII, a treatment for acute bleeding indications, as of April 12.

Roche, which was to lead late-stage clinical development of the drug candidate, cited the companies' inability to perform adequate de-risking prior to clinical trials. It has now relinquished all of its rights to the product back to Maxygen. The latter was down 75 cents, or 7.1%, to $9.75.

More from Investing

What Bad Weather? Kohl's Shares Spike as Same-Store Sales Jump

What Bad Weather? Kohl's Shares Spike as Same-Store Sales Jump

China Gives Tesla, Ford, General Motors and Trump One Awesome Present

China Gives Tesla, Ford, General Motors and Trump One Awesome Present

The Great American Supermarket No Longer Reigns Supreme

The Great American Supermarket No Longer Reigns Supreme

Kroger CEO: Even in the Age of Amazon, Physical Stores Will Still Be Important

Kroger CEO: Even in the Age of Amazon, Physical Stores Will Still Be Important

China to Slash Automobile Tariffs and 4 Other Stories You Must Know Tuesday

China to Slash Automobile Tariffs and 4 Other Stories You Must Know Tuesday